Overhaul drug development to refill pipelines, expert says

08/16/2012 | Forbes

Recent failures of highly anticipated drugs show that Big Pharma should "develop a more flexible approach to drug approval and patent exclusivity and change its business model to encourage more scientific collaboration among companies," writes Christopher Bowe, a U.S. health care analyst at Informa Scrip. Working more closely with regulators and payers, accepting sliding patent exclusivity based on comparative effectiveness, and loosening intellectual property protections to encourage more collaboration would help Big Pharma out of the doldrums, Bowe writes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC